ArticleObesity pillars2026
Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing prevalence of obesity is generating demand for chronic pharmacologic treatment, but Latin American evidence on population-level budget implications remains limited. Methods: This was an observational, cross-sectional descriptive study using ENDES (Encuesta Demográfica y de Salud Familiar or Demographic and Family Health Survey) 2022-2024 data, with a deterministic scenario-based budget impact analysis component. Survey-observable candidate populations and gross medication-acquisition requirements were estimated under the complex survey design. Liraglutide, extended-release naltrexone/bupropion, and extended-release phentermine/topiramate were modeled, while semaglutide 2.4 mg served as a supplementary non-governmental retail scenario. Results: The pooled file included 76,819 records. An estimated 7.54 million adults had Body Mass Index-defined obesity, 9.04 million met the broad criterion, and 3.67 million met pragmatic priority. At 100% coverage, broad-criterion annual budgets were S/142.95 billion for liraglutide, S/23.65 billion for the IETSI (Institute for Health Technology Assessment and Research)-reported naltrexone/bupropion scenario, and S/26.83 billion for phentermine/topiramate; corresponding pragmatic-priority budgets were S/57.95 billion, S/9.59 billion, and S/10.88 billion. Semaglutide 2.4 mg cost S/16,804.86 per patient in the first year and S/18,135.52 in a maintenance year. Conclusion: In Peru, a substantial proportion of adults meet survey-observable criteria for treatment with obesity medications. The broad criterion reaches more than nine million adults, whereas pragmatic priority reduces the initial candidate population to nearly four million. Projected budget impact is driven primarily by candidate-population size and annual medication cost. Liraglutide 3.0 mg and semaglutide 2.4 mg represent high-cost non-governmental retail scenarios rather than expected institutional procurement estimates. Extended-release naltrexone/bupropion provides a lower-cost non-GLP-1 comparator,and extended-release phentermine/topiramate was analyzed only as an exploratory supplementary comparator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.